A study on the effect of mTOR on VEGF showed that everolimus reduced human VEGF secretion by 20–45% in wild type and resistant cancer cell lines including GEO and GEO-GR (gefitinib resistant) colon cancer [77]. Here, VEGFA is linked to colonic neoplasm.